Zoetis Inc. (ZTS) Return on Invested Capital (ROIC): 21.54%
Is Zoetis Inc.’s return on invested capital (ROIC) high or low?
Zoetis Inc.'s return on invested capital (ROIC) of 21.54% is 12% above its 5-year average of 19.27%, near the high end of its 5-year range (15.44%–22.20%).
As of Thursday, June 11, 2026. 1.51% below its 12-month average of 21.87%.
ZTS Return on Invested Capital (ROIC) Chart
ZTS Average Return on Invested Capital (ROIC) Chart
ZTS Current vs Average Return on Invested Capital (ROIC) Chart
ZTS Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
21.54%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
21.87%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
20.30%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
19.27%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
16.93%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
14.60%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
13.74%
CURRENT VS TTM AVG
-1.51%
CURRENT VS 3Y AVG
+6.08%
CURRENT VS 5Y AVG
+11.81%
CURRENT VS 10Y AVG
+27.22%
CURRENT VS 15Y AVG
+47.52%
CURRENT VS 20Y AVG
+56.74%
ZTS Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zoetis Inc. (ZTS) | $34.27B | 21.54% | 21.87% | 20.30% | 19.27% |
| Agilent Technologies, Inc. (A) | $36.21B | 12.57% | 12.57% | 13.57% | 12.73% |
| Centene Corporation (CNC) | $32.26B | -13.41% | -4.17% | -0.53% | 0.76% |
| Medline Inc. (MDLN) | $30.90B | 5.69% | 6.03% | 3.95% | 3.95% |
| IQVIA Holdings Inc. (IQV) | $30.08B | 8.23% | 8.41% | 8.23% | 6.99% |
| Biogen Inc. (BIIB) | $28.94B | 6.62% | 7.71% | 8.64% | 10.90% |
| DexCom, Inc. (DXCM) | $28.92B | 16.61% | 13.40% | 11.07% | 9.62% |
| Veeva Systems Inc. (VEEV) | $26.31B | 9.48% | 9.25% | 9.54% | 11.31% |
| IDEXX Laboratories, Inc. (IDXX) | $43.84B | 40.27% | 37.07% | 34.89% | 35.94% |
| Humana Inc. (HUM) | $44.54B | 3.12% | 3.25% | 5.37% | 7.01% |
Capital Efficiency
ROIC
21.5%
ROE
81.8%
Zoetis Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Zoetis Inc. (ZTS)?
- The return on invested capital (ROIC) for ZTS stock is 21.54%.
- Is Zoetis Inc.'s return on invested capital (ROIC) high or low?
- Zoetis Inc.'s return on invested capital (ROIC) of 21.54% is 12% above its 5-year average of 19.27%, near the high end of its 5-year range (15.44%–22.20%).
- What is the TTM average return on invested capital (ROIC) for Zoetis Inc. (ZTS)?
- The TTM average return on invested capital (ROIC) for ZTS stock is 21.87%.
- What is the 3Y average return on invested capital (ROIC) for Zoetis Inc. (ZTS)?
- The 3Y average return on invested capital (ROIC) for ZTS stock is 20.30%.
- What is the 5Y average return on invested capital (ROIC) for Zoetis Inc. (ZTS)?
- The 5Y average return on invested capital (ROIC) for ZTS stock is 19.27%.
- What is the 10Y average return on invested capital (ROIC) for Zoetis Inc. (ZTS)?
- The 10Y average return on invested capital (ROIC) for ZTS stock is 16.93%.
- What is the 15Y average return on invested capital (ROIC) for Zoetis Inc. (ZTS)?
- The 15Y average return on invested capital (ROIC) for ZTS stock is 14.60%.
- What is the 20Y average return on invested capital (ROIC) for Zoetis Inc. (ZTS)?
- The 20Y average return on invested capital (ROIC) for ZTS stock is 13.74%.
Zoetis Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 21.54% |
| 2024-12-31 | 22.20% |
| 2023-12-31 | 19.73% |
| 2022-12-31 | 17.75% |
| 2021-12-31 | 18.93% |
| 2020-12-31 | 15.44% |
| 2019-12-31 | 16.42% |
| 2018-12-31 | 16.57% |
| 2017-12-31 | 13.03% |
| 2016-12-31 | 14.34% |
| 2015-12-31 | 10.30% |
| 2014-12-31 | 12.60% |
| 2013-12-31 | 11.60% |
| 2012-12-31 | 10.06% |
| 2011-12-31 | 8.84% |
| 2010-12-31 | 4.27% |
| 2009-12-31 | 0.00% |
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck